Inceptor Bio
Developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | $21.0m Valuation: $189m | Series A | |
| Total Funding | 000k | ||
Related Content
Inceptor Bio, a clinical-stage biotechnology firm founded in May 2020, is strategically positioned to address difficult-to-treat cancers through a diversified portfolio of next-generation cell therapies. The company was founded by Shailesh Maingi, who also founded and leads the life sciences venture capital firm Kineticos Ventures, a primary financial backer of Inceptor. This connection provides Inceptor with both capital and strategic guidance.
The company's core business revolves around advancing multiple cell therapy platforms, including CAR-T, CAR-M, and CAR-NK, from the discovery phase into clinical trials. A key component of its strategy is the in-house Advanced Manufacturing Platform (AMP+), a 29,000-square-foot GMP manufacturing facility in Gainesville, Florida, designed to ensure control over the production and supply of its therapeutic candidates. Inceptor's business model involves identifying and licensing promising technologies from academic institutions and then leveraging its integrated development and manufacturing capabilities to accelerate them toward clinical application. The company has established partnerships with entities like the University of Minnesota for its iPSC platform, Avectas for its Solupore cell engineering technology, and GRIT Bio for clinical development in China.
Inceptor's leading therapeutic candidate is IB-T101, an autologous CAR-T therapy targeting the CD70 protein, which is overexpressed in clear cell Renal Cell Carcinoma (ccRCC). This program is built upon the company's proprietary OUTLAST™ platform, which metabolically reprograms T cells to better survive and function within the hostile tumor microenvironment. The platform conditions the T cells to be more persistent and stem-like, enhancing their ability to combat solid tumors. In February 2025, Inceptor achieved a significant milestone by dosing the first patient in a Phase 1 clinical trial for IB-T101. This trial is evaluating the safety, tolerability, and preliminary efficacy in ccRCC patients who have relapsed after other treatments. The company's revenue generation will likely depend on milestone payments from partnerships and, ultimately, the commercialization of its therapies.
Keywords: cell therapy, CAR-T, oncology, solid tumors, tumor microenvironment, CAR-M, CAR-NK, renal cell carcinoma, CD70, GMP manufacturing